34 completed, 5 not yet recruiting, 4 terminated, 3 recruiting. 52 Phase 1, 18 Phase 2.
Follow Papillomavirus Infections: new trials by email Literature Review of Papillomavirus Infections trials Research Report on Papillomavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine 10vHPV, Gardasil9 - Human Papillomavirus Infection | Phase 1 / Phase 2 | Not yet recruiting | Serum Institute of India Pvt. Ltd. | 72 | 2026-11-01 | 2026-11-06 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Safety and Immunogenicity of HPV Vaccine in HIV-infected HPV vaccination - HIV-infected Individuals | Phase 1 / Phase 2 | Not yet recruiting | Beijing 302 Hospital | 80 | 2026-09-01 | 2026-09-01 |
| Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL) BBM-C101 - High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Mianyi Biopharmaceutical Co., Ltd. | 60 | 2026-06-17 | 2026-06-25 |
| A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D) - Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma | Phase 1 / Phase 2 | Recruiting | Cellid Co., Ltd. | 37 | 2026-02-04 | 2026-07-08 |
| Tolerance and Effectiveness of C14 on HPV Infection The monoterpenoid zinc tetra-ascorbo-camphorate ("C14"), Distilled water group - HPV-induced Cancers, HPV Infections | Phase 1 / Phase 2 | Not yet recruiting | MGB Pharma | 66 | 2024-11-15 | 2024-11-04 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years Placebo, 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha) - HPV Infection, HPV-Related Carcinoma | Phase 1 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 72 | 2024-08-03 | 2025-01-06 |
| Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts ABI-2280 - Human Papillomavirus Infection | Phase 1 / Phase 2 | Completed | Antiva Biosciences | 141 | 2024-03-27 | 2026-08-17 |
| Interferon Alpha Therapy for Cervical CINI and HPV Infection gel Interferon arm, gel Interferon and interferon suppository arm - Cervical Dysplasia, HPV Infection | Phase 1 | Completed | Mongolian National University of Medical Sciences | 60 | 2023-11-07 | 2025-04-03 |
| Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women FluBHPVE6E7, Placebo - HPV Infection, HPV-Related Cervical Carcinoma | Phase 1 | Recruiting | BlueSky Immunotherapies GmbH | 20 | 2023-09-12 | 2025-02-14 |
| Phase I Clinical Trial of a Candidate HPV Vaccine Human papillomavirus (HPV) Vaccine, Placebo - Human Papillomavirus Infection | Phase 1 | Unknown | Wuhan BravoVax Co., Ltd. | 40 | 2023-08-01 | 2023-01-06 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Placebo among 18-45 yrs, Placebo among 9-17 yrs - Penile Cancer, Anal Cancer | Phase 1 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 90 | 2022-09-23 | 2024-04-17 |
| A Phase 1 Study of PV-001 9-valent Human Papillomavirus(HPV) Vaccine PV-001, PEV-001 - HPV Infections | Phase 1 | Completed | POSVAX | 41 | 2022-08-17 | 2025-07-23 |
| Intralesional HPV Vaccine for Condylomata nonavalent human papillomavirus vaccine - Human Papilloma Virus, Warts | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 2 | 2022-04-15 | 2025-10-02 |
| Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions ChAdOx1-HPV, MVA-HPV, Placebo - HPV Infection, CIN1 | Phase 1 / Phase 2 | Completed | Barinthus Biotherapeutics | 108 | 2021-03-16 | 2025-08-28 |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2 - Recurrent Respiratory Papillomatosis, Papillomavirus Infections | Phase 1 / Phase 2 | Active not recruiting | Precigen, Inc | 38 | 2021-03-16 | 2025-06-11 |
| Study of FluBHPVE6E7 in HPV-16 Infected Women FluBHPVE6E7 - HPV Infection | Phase 1 | Completed | BlueSky Immunotherapies GmbH | 28 | 2020-12-09 | 2023-06-26 |
| A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), Placebo - HPV Infection, HPV-Related Cervical Carcinoma | Phase 1 | Completed | National Vaccine and Serum Institute, China | 90 | 2019-09-07 | 2021-11-24 |
Showing 20 of 52. Sign in to see all of them.
Condylomata Acuminata (15) · Uterine Cervical Neoplasms (12) · Warts (7) · Vulvar Neoplasms (5) · Anus Neoplasms (4) · HIV Infections (4) · Uterine Cervical Dysplasia (3) · Vaginal Neoplasms (3) · Agammaglobulinemia (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Immunologic Deficiency Syndromes (2) · Neoplasms (2) · Precancerous Conditions (2)
DNA Virus Infections (52) · Tumor Virus Infections (52) · Infections (51) · Virus Diseases (51) · Communicable Diseases (46) · Disease Attributes (46) · Genital Diseases (46) · Pathologic Processes (46) · Pathological Conditions, Signs and Symptoms (46) · Sexually Transmitted Diseases, Viral (46) · Urogenital Diseases (46) · Sexually Transmitted Diseases (44) · Skin Diseases (23) · Skin and Connective Tissue Diseases (23) · Skin Diseases, Infectious (21)
Papillomavirus Vaccines (5) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (3) · 3-ingenyl angelate (2) · Cidofovir (2) · Cyclophosphamide (2) · Interleukin-2 (2) · Vaccines (2) · fludarabine (2) · human papillomavirus vaccine, L1 type 16, 18 (2) · plerixafor (2) · Acetaminophen (1) · Atropine (1) · Biopsy (1) · Brachytherapy (1) · Busulfan (1)
Shanghai Bovax Biotechnology Co., Ltd. (4) · Antiva Biosciences (3) · Gilead Sciences (3) · GlaxoSmithKline (3) · BlueSky Immunotherapies GmbH (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · 2A Pharma AB (1) · AIDS Malignancy Consortium (1) · Abramson Cancer Center at Penn Medicine (1) · Anaconda Pharma (1) · Barinthus Biotherapeutics (1) · Beijing 302 Hospital (1) · Beijing Health Guard Biotechnology, Inc (1) · BioMAS Ltd (1)
United States (16) · China (11) · Australia (6) · Belgium (3) · France (3) · United Kingdom (3) · Canada (2) · Germany (2) · South Korea (2) · Argentina (1) · Austria (1) · Bolivia (1) · Democratic Republic of the Congo (1) · Estonia (1) · India (1)
Jun Zhang, Master (2) · Amy Lankford, PhD (1) · Angela Smith (1) · Ayan Kusari, MD (1) · Batsuren Choijamts, Ph.D (1) · Christina Chu, MD (1) · David Bell (1) · David H McDermott, M.D. (1) · Edgar Valdez, MD (1) · Elsa Mondou, MD (1) · Eric Deutsch, MD (1) · Hitt Sharma (1)
PMID 21890643, PMID 24523241, PMID 24576907, PMID 24674663, PMID 24723677, PMID 24731816, PMID 26176261, PMID 26980480, PMID 30715452, PMID 33558725, PMID 35834812, PMID 37283969, PMID 38932417, PMID 40221095, PMID 40330596, PMID 41048471, PMID 41276263, PMID 41403292, PMID 42266673, PMID 42627231
2018 (2), 2016 (1), 2023 (1), U01CA121947 (1)